In Europe, a Medical Device Accelerator Takes Root

Device giant Medtronic and venture capital leader Sofinnova have teamed up to see if they can help seed the promising ground of device start-ups in Europe, providing an outlet for novel ideas of the continent's physicians.

One of Europe's leading venture capital firms, Paris-based Sofinnova Partners, and device-industry powerhouse Medtronic PLC have announced plans to launch a new medical device incubator or accelerator in Europe—born out of what executives at both companies see as a fundamental disconnect between the clinical and technological richness of Europe and the practical reality of starting a company there. The new organization, designed to take advantage of what both companies believe is a wealth of untapped potential for new device ideas from European physicians, is located on the campus of the Ecole Polytechnique Federal Institute of Lausanne (EPFL), one of the leading technical institutes in Europe.

"If you look at the top 100 products that we sell at Medtronic--coronary stents or angioplasty, artificial disks or cardiac resynchronization or deep brain stimulation--and ask simply, where did the idea come from, what you find is that almost 100% of the time they came from physicians and, in many cases, physicians located somewhere in Europe," says Stephen Oesterle, MD, Medtronic's SVP for medicine and technology, who points to Swiss innovators like Andreas Gruntzig, MD, the father of angioplasty, and Ulrich Sigwart, MD, who

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

More from Geography

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

How Structured Patient Engagement Gives Medtech Companies A Competitive Edge

 

Communication with patients has become a particularly crucial factor for investors, payers, and other healthcare decision-makers in a hostile market environment.